Nuzenio

Adc Cancer Drug

Adc Cancer Drug news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 7 latest news signals 7 publisher sources 100/100 entity strength

Latest news

Timeline

Mon, 10 Aug 2026 04:31:46 GMTAkeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer - The Manila Times
Sat, 08 Aug 2026 11:14:59 GMTHERTHENA-Breast02 Trial: Innovative Dual-ADC Strategy in HR+/HER2-Low Breast Cancer - Oncodaily
Fri, 07 Aug 2026 06:05:00 GMTLigaChem Biosciences Takes Solo Control of ADC Cancer Drug After NextCure's Strategic Pivot - finance.biggo.com
Tue, 04 Aug 2026 00:00:00 GMTPathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC - Business Wire
Mon, 03 Aug 2026 17:14:14 GMTCombination of targeted therapies could help overcome treatment resistance in advanced prostate cancer - UCLA Health
Mon, 03 Aug 2026 13:59:35 GMTFDA Fast Track and Priority Review Designations Granted in July 2026 - Oncology News Central

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Adc Cancer Drug.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

7 distinct publisher/source names are currently connected to this entity page.